Your browser doesn't support javascript.
loading
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq, Gabrielle; Haegel, Hélène; Schneider, Anneliese; Giusti, Anna Maria; Marrer-Berger, Estelle; Boetsch, Christophe; Walz, Antje-Christine; Pulko, Vesna; Sam, Johannes; Challier, John; Ferlini, Cristiano; Odermatt, Alex; Umaña, Pablo; Bacac, Marina; Klein, Christian.
Afiliación
  • Leclercq G; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland gabrielle.leclercq@roche.com.
  • Haegel H; Department of Pharmaceutical Sciences, Division of Molecular and Systems Toxicology, University of Basel, Basel, Switzerland.
  • Schneider A; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Giusti AM; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Marrer-Berger E; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Boetsch C; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Walz AC; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Pulko V; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Sam J; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Challier J; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Ferlini C; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Odermatt A; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Umaña P; Department of Pharmaceutical Sciences, Division of Molecular and Systems Toxicology, University of Basel, Basel, Switzerland.
  • Bacac M; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
  • Klein C; Roche Pharma Research and Early Development, Roche Innovation Centre Zurich, Schlieren, Switzerland.
J Immunother Cancer ; 9(7)2021 07.
Article en En | MEDLINE | ID: mdl-34326166
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Citocinas / Anticuerpos Biespecíficos / Dasatinib / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Citocinas / Anticuerpos Biespecíficos / Dasatinib / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido